{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:51:27Z","timestamp":1794329487677,"version":"4.9.0"},"reference-count":138,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Sickle cell disease (SCD) is one of the commonest severe inherited disorders in the world. Infection accounts for a significant amount of the morbidity and mortality, particularly in sub-Saharan Africa, but is relatively poorly studied and characterized. Patients with SCD have significant immunodeficiency and are more likely to suffer severe and life-threatening complications of infection, and additionally infections can trigger complications of SCD itself. Those with more severe forms of SCD have functional asplenia from a very early age, which accounts for much of the morbidity in young children, particularly invasive infections from encapsulated bacteria including Streptococcus pneumoniae, Haemophilus influenzae, Salmonella typhi and meningococcal disease. Additionally, there are other defects in immune function in SCD, associated with anemia, tissue infarction and impaired adaptive immunity. Complications of infections in SCD include acute chest syndrome, acute painful episodes, osteomyelitis, meningitis, urinary tract infections, overwhelming sepsis and death. Viral infections cause significant morbidity, particularly severe anemia associated with parvovirus, and to a lesser extent other infections such as influenza and coronavirus disease 2019. The relationship between malaria and SCD is complicated and discussed in this review. Unlike many of the genetic risk factors for poor outcomes in SCD, it is theoretically possible to modify the risks associated with infections with established public health measures. These include the provision of vaccination, prophylactic antibiotics and access to clean water and mosquito avoidance, although current financial restraints and political priorities have made this difficult.<\/jats:p>","DOI":"10.3324\/haematol.2024.285066","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T11:03:22Z","timestamp":1732187002000},"page":"546-561","source":"Crossref","is-referenced-by-count":27,"title":["Infections in sickle cell disease"],"prefix":"10.3324","volume":"110","author":[{"given":"Lily E.A.","family":"Scourfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Nardo-Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas N.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"72594","doi-asserted-by":"crossref","unstructured":"Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017; 376(16):1561-1573.","DOI":"10.1056\/NEJMra1510865"},{"key":"72595","doi-asserted-by":"crossref","unstructured":"King H, Shumacker HB. Splenic studies: I. Susceptibility to infection after splenectomy performed in infancy. Ann Surg. 1952; 136(2):239-242.","DOI":"10.1097\/00000658-195208000-00006"},{"key":"72596","doi-asserted-by":"crossref","unstructured":"Pearson HA, Gallagher R, Chilcote R. Developmental pattern of splenic dysfunction in sickle cell disorders. Pediatrics. 1985; 76(3):392-397.","DOI":"10.1542\/peds.76.3.392"},{"key":"72597","doi-asserted-by":"crossref","unstructured":"Diggs LW. Siderofibrosis of the spleen in sickle cell anemia. J Am Med Assoc. 1935; 104(7):538-541.","DOI":"10.1001\/jama.1935.02760070020005"},{"key":"72598","doi-asserted-by":"crossref","unstructured":"Nardo-Marino A, Glenth\u00f8j A, Brewin JN. The significance of spleen size in children with sickle cell anemia. Am J Hematol. 2022; 97(12):1520-1528.","DOI":"10.1002\/ajh.26703"},{"key":"72599","doi-asserted-by":"crossref","unstructured":"Rogers ZR, Wang WC, Luo Z. Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG trial. Blood. 2011; 117(9):2614-2617.","DOI":"10.1182\/blood-2010-04-278747"},{"key":"72600","doi-asserted-by":"crossref","unstructured":"Cottas de Azevedo JT, Malmegrim KCR. Immune mechanisms involved in sickle cell disease pathogenesis: current knowledge and perspectives. Immunol Lett. 2020; 224:1-11.","DOI":"10.1016\/j.imlet.2020.04.012"},{"key":"72601","doi-asserted-by":"crossref","unstructured":"Tubman VN, Maysonet D, Estrada N. Unswitched memory B cell deficiency in children with sickle cell disease and response to pneumococcal polysaccharide vaccine. Am J Hematol. 2024; 99(6):1084-1094.","DOI":"10.1002\/ajh.27319"},{"key":"72602","doi-asserted-by":"crossref","unstructured":"Telfer P, Coen P, Chakravorty S. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica. 2007; 92(7):905-912.","DOI":"10.3324\/haematol.10937"},{"key":"72603","doi-asserted-by":"crossref","unstructured":"Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood. 2010; 115(17):3447-3452.","DOI":"10.1182\/blood-2009-07-233700"},{"key":"72604","doi-asserted-by":"crossref","unstructured":"Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet. 2001; 357(9257):680-683.","DOI":"10.1016\/S0140-6736(00)04132-5"},{"key":"72605","doi-asserted-by":"crossref","unstructured":"Pearson HA, Spencer RP, Cornelius EA. Functional asplenia in sickle-cell anemia. N Engl J Med. 1969; 281(17):923-926.","DOI":"10.1056\/NEJM196910232811703"},{"key":"72606","unstructured":"Gaston M, Rosse WF. The cooperative study of sickle cell disease: review of study design and objectives. Am J Pediatr Hematol Oncol. 1982; 4(2):197-201."},{"key":"72607","doi-asserted-by":"crossref","unstructured":"Gaston MH, Verter JI, Woods G. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med. 1986; 314(25):1593-1599.","DOI":"10.1056\/NEJM198606193142501"},{"key":"72608","doi-asserted-by":"crossref","unstructured":"Facchin A, Bui S, Leroux S. Variability of ciprofloxacin pharmacokinetics in children: impact on dose range in sickle cell patients. J Antimicrob Chemother. 2018; 73(12):3423-3429.","DOI":"10.1093\/jac\/dky328"},{"key":"72609","unstructured":"A sickle crisis?. National confidential enquiry into patient outcome and death. 2008. Publisher Full Text|"},{"key":"72610","doi-asserted-by":"crossref","unstructured":"Vichinsky EP, Neumayr LD, Earles AN. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000; 342(25):1855-1865.","DOI":"10.1056\/NEJM200006223422502"},{"key":"72611","doi-asserted-by":"crossref","unstructured":"Howard J, Hart N, Roberts-Harewood M, Cummins M, Awogbade M, Davis B. Guideline on the management of acute chest syndrome in sickle cell disease. Br J Haematol. 2015; 169(4):492-505.","DOI":"10.1111\/bjh.13348"},{"key":"72612","doi-asserted-by":"crossref","unstructured":"Gonzales J, Chakraborty T, Romero M. Streptococcus pneumoniae and its virulence factors H2O2 and pneumolysin are potent mediators of the acute chest syndrome in sickle cell disease. Toxins (Basel). 2021; 13(2):157.","DOI":"10.3390\/toxins13020157"},{"key":"72613","doi-asserted-by":"crossref","unstructured":"Powars D, Overturf G, Turner E. Is there an increased risk of Haemophilus influenzae septicemia in children with sickle cell anemia?. Pediatrics. 1983; 71(6):927-931.","DOI":"10.1542\/peds.71.6.927"},{"key":"72614","doi-asserted-by":"crossref","unstructured":"Wong W-Y, Overturf GD, Powars DR. Infection caused by Streptococcus pneumoniae in children with sickle cell disease: epidemiology, immunologic mechanisms, prophylaxis, and vaccination. Clin Infect Dis. 1992; 14(5):1124-1136.","DOI":"10.1093\/clinids\/14.5.1124"},{"key":"72615","doi-asserted-by":"crossref","unstructured":"Miller ML, Gao G, Pestina T, Persons D, Tuomanen E. Hypersusceptibility to invasive pneumococcal infection in experimental sickle cell disease involves platelet-activating factor receptor. J Infect Dis. 2007; 195(4):581-584.","DOI":"10.1086\/510626"},{"key":"72616","doi-asserted-by":"crossref","unstructured":"Halasa NB, Shankar SM, Talbot TR. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007; 44(11):1428-1433.","DOI":"10.1086\/516781"},{"key":"72617","doi-asserted-by":"crossref","unstructured":"Assad Z, Michel M, Valtuille Z. Incidence of acute chest syndrome in children with sickle cell disease following implementation of the 13-valent pneumococcal conjugate vaccine in France. JAMA Netw Open. 2022; 5(8):e2225141.","DOI":"10.1001\/jamanetworkopen.2022.25141"},{"key":"72618","doi-asserted-by":"crossref","unstructured":"Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med. 2011; 41(6 Suppl 4):S398-405.","DOI":"10.1016\/j.amepre.2011.09.013"},{"key":"72619","doi-asserted-by":"crossref","unstructured":"Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013; 10(7):e1001484.","DOI":"10.1371\/journal.pmed.1001484"},{"key":"72620","doi-asserted-by":"crossref","unstructured":"Williams TN. Sickle cell disease in sub-Saharan Africa. Hematol Oncol Clin North Am. 2016; 30(2):343-358.","DOI":"10.1016\/j.hoc.2015.11.005"},{"key":"72621","doi-asserted-by":"crossref","unstructured":"De Montalembert M, Abboud MR, Fiquet A. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): results of a phase 3 study. Pediatr Blood Cancer. 2015; 62(8):1427-1436.","DOI":"10.1002\/pbc.25502"},{"key":"72622","doi-asserted-by":"crossref","unstructured":"Davies JM, Lewis MPN, Wimperis J, Rafi I, Ladhani S, Bolton\u2010 Maggs PHB. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a Working Party of the Haemato\u2010Oncology Task Force. Br J Haematol. 2011; 155(3):308-317.","DOI":"10.1111\/j.1365-2141.2011.08843.x"},{"key":"72623","doi-asserted-by":"crossref","unstructured":"Gill FM, Sleeper LA, Weiner SJ. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood. 1995; 86(2):776-783.","DOI":"10.1182\/blood.V86.2.776.bloodjournal862776"},{"key":"72624","doi-asserted-by":"crossref","unstructured":"Yee ME, Bakshi N, Graciaa SH. Incidence of invasive Haemophilus influenzae infections in children with sickle cell disease. Pediatr Blood Cancer. 2019; 66(6)","DOI":"10.1002\/pbc.27642"},{"key":"72625","doi-asserted-by":"crossref","unstructured":"Ellison AM, Ota KV, McGowan KL, Smith-Whitley K. Epidemiology of bloodstream infections in children with sickle cell disease. Pediatr Infect Dis J. 2013; 32(5):560-563.","DOI":"10.1097\/INF.0b013e318286c75b"},{"key":"72626","doi-asserted-by":"crossref","unstructured":"Williams TN, Uyoga S, Macharia A. Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study. Lancet. 2009; 374(9698):1364-1370.","DOI":"10.1016\/S0140-6736(09)61374-X"},{"key":"72627","doi-asserted-by":"crossref","unstructured":"Allali S, Chalumeau M, Launay O, Ballas SK, de Montalembert M. Conjugate Haemophilus influenzae type b vaccines for sickle cell disease. Cochrane Database System Rev. 2018; 8(8):CD011199.","DOI":"10.1002\/14651858.CD011199.pub3"},{"key":"72628","doi-asserted-by":"crossref","unstructured":"Campbell LA, Kuo C. Chlamydia pneumoniae-an infectious risk factor for atherosclerosis?. Nat Rev Microbiol. 2004; 2(1):23-32.","DOI":"10.1038\/nrmicro796"},{"key":"72629","doi-asserted-by":"crossref","unstructured":"Miller ST, Hammerschlag MR, Chirgwin K. Role of Chlamydia pneumoniae in acute chest syndrome of sickle cell disease. J Pediatr. 1991; 118(1):30-33.","DOI":"10.1016\/S0022-3476(05)81839-6"},{"key":"72630","doi-asserted-by":"crossref","unstructured":"Dean D, Neumayr L, Kelly DM. Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell disease. J Pediatr Hematol Oncol. 2003; 25(1):46-55.","DOI":"10.1097\/00043426-200301000-00010"},{"key":"72631","doi-asserted-by":"crossref","unstructured":"Goyal M, Miller ST, Hammerschlag MR. Is Chlamydia pneumoniae infection associated with stroke in children with sickle cell disease?. Pediatrics. 2004; 113(4):e318-e321.","DOI":"10.1542\/peds.113.4.e318"},{"key":"72632","unstructured":"Chlamydia pneumoniae Infection | CDC. 2024. Publisher Full Text|"},{"key":"72633","doi-asserted-by":"crossref","unstructured":"Ferwerda A, Moll HA, de Groot R. Respiratory tract infections by Mycoplasma pneumoniae in children: a review of diagnostic and therapeutic measures. Eur J Pediatr. 2001; 160(8):483-491.","DOI":"10.1007\/s004310100775"},{"key":"72634","doi-asserted-by":"crossref","unstructured":"Neumayr L, Lennette E, Kelly D. Mycoplasma disease and acute chest syndrome in sickle cell disease. Pediatrics. 2003; 112(1 Pt 1):87-95.","DOI":"10.1542\/peds.112.1.87"},{"key":"72635","doi-asserted-by":"crossref","unstructured":"Shulman ST, Bartlett J, Clyde WA, Ayoub EM. The unusual severity of Mycoplasmal pneumonia in children with sickle-cell disease. N Engl J Med. 1972; 287(4):164-167.","DOI":"10.1056\/NEJM197207272870403"},{"key":"72636","unstructured":"Scenario: Prevention of complications | Management | Sickle cell disease | CKS | NICE. 2024. Publisher Full Text|"},{"key":"72637","unstructured":"UK Health Security Agency. Routine childhood immunisations from 1 September 2023. 2024. Publisher Full Text|"},{"key":"72638","doi-asserted-by":"crossref","unstructured":"Chen C, Bakeera\u2010Kitaka S, Mupere E. Paediatric immunisation and chemoprophylaxis in a Ugandan sickle cell disease clinic. J Paediatr Child Health. 2019; 55(7):795-801.","DOI":"10.1111\/jpc.14291"},{"key":"72639","doi-asserted-by":"crossref","unstructured":"Gorham MW, Smith CR, Smith SK, Wong L, Kreze O. Vaccinations in sickle cell disease: an audit of vaccination uptake in sickle cell patients attending Newham University Hospital. Vaccine. 2015; 33(38):5005-5011.","DOI":"10.1016\/j.vaccine.2015.06.028"},{"key":"72640","doi-asserted-by":"crossref","unstructured":"Jarovsky D, Bastos PR, de Matos SF. Vaccination in pediatric patients with sickle-cell disease: uptake report and mini-review. J Trop Pediatr. 2022; 68(3):fmac034.","DOI":"10.1093\/tropej\/fmac034"},{"key":"72641","doi-asserted-by":"crossref","unstructured":"Lebensburger JD, Howard T, Hu Y. Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin. Blood. 2012; 119(8):1915-1921.","DOI":"10.1182\/blood-2011-08-374447"},{"key":"72642","doi-asserted-by":"crossref","unstructured":"Pearson HA. Sickle cell anemia and severe infections due to encapsulated bacteria. J Infect Dis. 1977; 136(Suppl):S25-30.","DOI":"10.1093\/infdis\/136.Supplement.S25"},{"key":"72643","doi-asserted-by":"crossref","unstructured":"Sobota A, Sabharwal V, Fonebi G, Steinberg M. How we prevent and manage infection in sickle cell disease. Br J Haematol. 2015; 170(6):757-767.","DOI":"10.1111\/bjh.13526"},{"key":"72644","doi-asserted-by":"crossref","unstructured":"Berger E, Saunders N, Wang L, Friedman JN. Sickle cell disease in children: differentiating osteomyelitis from vaso-occlusive crisis. Arch Pediatr Adolesc Med. 2009; 163(3):251-255.","DOI":"10.1001\/archpediatrics.2008.545"},{"key":"72645","doi-asserted-by":"crossref","unstructured":"Neonato MG, Guilloud\u2010Bataille M, Beauvais P. Acute clinical events in 299 homozygous sickle cell patients living in France. Eur J Haematol. 2000; 65(3):155-164.","DOI":"10.1034\/j.1600-0609.2000.90210.x"},{"key":"72646","doi-asserted-by":"crossref","unstructured":"Burnett MW, MD JWB, Cook BA. Etiology of osteomyelitis complicating sickle cell disease. Pediatrics. 1998; 101(2):296-297.","DOI":"10.1542\/peds.101.2.296"},{"key":"72647","unstructured":"Thanni LO. Bacterial osteomyelitis in major sickling haemoglobinopathies: geographic difference in pathogen prevalence. Afr Health Sci. 2006; 6(4):236-239."},{"key":"72648","unstructured":"Gaschignard J, Koehl B, Rees DC. Invasive bacterial infections in children with sickle cell disease: 2014-2019. Pediatrics. 2023; 152(4):e2022061061."},{"key":"72649","doi-asserted-by":"crossref","unstructured":"Kavanagh N, Ryan EJ, Widaa A. Staphylococcal osteomyelitis: disease progression, treatment challenges, and future directions. Clin Microbiol Rev. 2018; 31(2):e00084-17.","DOI":"10.1128\/CMR.00084-17"},{"key":"72650","doi-asserted-by":"crossref","unstructured":"Gimza BD, Cassat JE. Mechanisms of antibiotic failure during Staphylococcus aureus osteomyelitis. Front Immunol. 2021; 12:638085.","DOI":"10.3389\/fimmu.2021.638085"},{"key":"72651","doi-asserted-by":"crossref","unstructured":"Ochocinski D, Dalal M, Black LV. Life-threatening infectious complications in sickle cell disease: a concise narrative review. Front Pediatr. 2020; 8:38.","DOI":"10.3389\/fped.2020.00038"},{"key":"72652","doi-asserted-by":"crossref","unstructured":"Zarkowsky HS, Gallagher D, Gill FM. Bacteremia in sickle hemoglobinopathies. J Pediatr. 1986; 109(4):579-585.","DOI":"10.1016\/S0022-3476(86)80216-5"},{"key":"72653","doi-asserted-by":"crossref","unstructured":"Sadat-Ali M, Al-Umran K, Al-Habdan I, Al-Mulhim F. Ultrasonography: can it differentiate between vasoocclusive crisis and acute osteomyelitis in sickle cell disease?. J Pediatr Orthop. 1998; 18(4):552-554.","DOI":"10.1097\/01241398-199807000-00030"},{"key":"72654","doi-asserted-by":"crossref","unstructured":"Lim SH, Meth\u00e9 BA, Knoll BM, Morris A, Obaro SK. Invasive non-typhoidal Salmonella in sickle cell disease in Africa: is increased gut permeability the missing link?. J Transl Med. 2018; 16(1):239.","DOI":"10.1186\/s12967-018-1622-4"},{"key":"72655","doi-asserted-by":"crossref","unstructured":"Odey F, Okomo U, Oyo-Ita A. Vaccines for preventing invasive salmonella infections in people with sickle cell disease. Cochrane Database Syst Rev. 2018; 12(12):CD006975.","DOI":"10.1002\/14651858.CD006975.pub4"},{"key":"72656","doi-asserted-by":"crossref","unstructured":"Hashimi AZA, Fazari EA, Ward MA. Predictors of developing a complex course of osteomyelitis in patients with sickle cell anaemia. Sultan Qaboos Univ Med J. 2024; 24(1):58-62.","DOI":"10.18295\/squmj.12.2023.083"},{"key":"72657","doi-asserted-by":"crossref","unstructured":"Bassam Hamieh N, Abdul Hamid Abou Layla H, Ali Ali R, Bayram Z, Bizri AR. Bacteroides fragilis acute hematogenous osteomyelitis in a young female with sickle cell disease. Case Rep Infect Dis. 2023; 2023:6340222.","DOI":"10.1155\/2023\/6340222"},{"key":"72658","doi-asserted-by":"crossref","unstructured":"Khalife S, Hanna-Wakim R, Ahmad R. Emergence of Gramnegative organisms as the cause of infections in patients with sickle cell disease. Pediatr Blood Cancer. 2021; 68(1):e28784.","DOI":"10.1002\/pbc.28784"},{"key":"72659","doi-asserted-by":"crossref","unstructured":"Kooy A, de Heide LJ, ten Tije AJ. Vertebral bone destruction in sickle cell disease: infection, infarction or both. Neth J Med. 1996; 48(6):227-231.","DOI":"10.1016\/0300-2977(95)00075-5"},{"key":"72660","doi-asserted-by":"crossref","unstructured":"Pszolla N, Sarkar MR, Strecker W. Buruli ulcer: a systemic disease. Clin Infect Dis. 2003; 37(6):e78-82.","DOI":"10.1086\/377170"},{"key":"72661","doi-asserted-by":"crossref","unstructured":"Al Farii H, Zhou S, Albers A. Management of osteomyelitis in sickle cell disease. J Am Acad Orthop Surg Glob Res Rev. 2020; 4(9):e20.","DOI":"10.5435\/JAAOSGlobal-D-20-00002"},{"key":"72662","doi-asserted-by":"crossref","unstructured":"Marti-Carvajal AJ, Agreda-Perez LH. Antibiotics for treating osteomyelitis in people with sickle cell disease. Cochrane Database Syst Rev. 2019; 10(10):CD007175.","DOI":"10.1002\/14651858.CD007175.pub5"},{"key":"72663","doi-asserted-by":"crossref","unstructured":"Chekroun M, Ch\u00e9rifi H, Fournier B. Oral manifestations of sickle cell disease. Br Dent J. 2019; 226(1):27-31.","DOI":"10.1038\/sj.bdj.2019.4"},{"key":"72664","unstructured":"Nguyen N, Ashong D. Neisseria meningitidis. 2024. Publisher Full Text|"},{"key":"72665","doi-asserted-by":"crossref","unstructured":"Sharma A, Alavi A, Woldie IL, Singh V. National burden of encapsulated bacterial infections in sickle cell disease. Blood. 2022; 140(Supplement 1):5148-5149.","DOI":"10.1182\/blood-2022-167224"},{"key":"72666","doi-asserted-by":"crossref","unstructured":"Feldman C, Anderson R. Meningococcal pneumonia: a review. Pneumonia (Nathan). 2019; 11(1):3.","DOI":"10.1186\/s41479-019-0062-0"},{"key":"72667","doi-asserted-by":"crossref","unstructured":"Patel N, Farooqi A, Callaghan M, Sethuraman U. Urinary tract infection in febrile children with sickle cell disease who present to the emergency room with fever. J Clin Med. 2020; 9(5):1531.","DOI":"10.3390\/jcm9051531"},{"key":"72668","doi-asserted-by":"crossref","unstructured":"Sangeda RZ, Yohana J, Jonathan A, Manyanga VP, Soka D, Makani J. Prevalence of urinary tract infections and antibiogram of bacteria isolated from children with sickle cell disease in Tanzania. Cureus. 2024; 16(4):e58786.","DOI":"10.7759\/cureus.58786"},{"key":"72669","doi-asserted-by":"crossref","unstructured":"Musonda T, Zulu M, Samutela M. Leucocytosis and asymptomatic urinary tract infections in sickle cell patients at a tertiary hospital in Zambia. Anemia. 2020; 2:2020.","DOI":"10.1155\/2020\/3792728"},{"key":"72670","doi-asserted-by":"crossref","unstructured":"Faletta JM, Woods GM, Verter JI. Discontinuing penicillin prophylaxis in children with sickle cell anemia. J Pediatr. 1995; 1279(5):685-690.","DOI":"10.1016\/S0022-3476(95)70154-0"},{"key":"72671","doi-asserted-by":"crossref","unstructured":"Adamkiewicz TV, Yee ME, Thomas S. Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines. Blood Adv. 2023; 7(21):6751-6761.","DOI":"10.1182\/bloodadvances.2022009643"},{"key":"72672","doi-asserted-by":"crossref","unstructured":"Yawn BP, Buchanan GR, Afenyi-Annan AN. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014; 312(10):1033-1048.","DOI":"10.1001\/jama.2014.10517"},{"key":"72673","doi-asserted-by":"crossref","unstructured":"Brown BJ, Madu A, Sangeda RZ. Utilization of pneumococcal vaccine and penicillin prophylaxis in sickle cell disease in three African countries: assessment among healthcare providers in SickleInAfrica. Hemoglobin. 2021; 45(3):163-170.","DOI":"10.1080\/03630269.2021.1954943"},{"key":"72674","doi-asserted-by":"crossref","unstructured":"Namazzi R, Bond C, Conroy AL. Hydroxyurea reduces infections in children with sickle cell anemia in Uganda. Blood. 2024; 143(14):1425-1428.","DOI":"10.1182\/blood.2023021575"},{"key":"72675","doi-asserted-by":"crossref","unstructured":"Aygun B, Lane A, Smart LR. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1\/2 trial. Lancet Haematol. 2024; 11(6):e425-e435.","DOI":"10.1016\/S2352-3026(24)00078-4"},{"key":"72676","doi-asserted-by":"crossref","unstructured":"Jayaraman S, Chalabi Z, Perel P, Guerriero C, Roberts I. The risk of transfusion\u2010transmitted infections in sub\u2010Saharan Africa. Transfusion. 2010; 50(2):433-442.","DOI":"10.1111\/j.1537-2995.2009.002402.x"},{"key":"72677","doi-asserted-by":"crossref","unstructured":"Panicker J, Harris RG, Smith SD. Coinfection with parvovirus B19 and Epstein Barr virus in an adolescent with sickle cell disease manifesting as septic shock. Blood. 2011; 118(21):4854.","DOI":"10.1182\/blood.V118.21.4854.4854"},{"key":"72678","doi-asserted-by":"crossref","unstructured":"Soltani S, Zakeri A, Tabibzadeh A. A literature review on the parvovirus B19 infection in sickle cell anemia and \u03b2-thalassemia patients. Trop Med Health. 2020; 48(1):96.","DOI":"10.1186\/s41182-020-00284-x"},{"key":"72679","doi-asserted-by":"crossref","unstructured":"Ogunsile FJ, Currie KL, Rodeghier M, Kassim A, DeBaun MR, Sharma D. History of parvovirus B19 infection is associated with silent cerebral infarcts. Pediatr Blood Cancer. 2018; 65(1):e26767.","DOI":"10.1002\/pbc.26767"},{"key":"72680","doi-asserted-by":"crossref","unstructured":"Smith-Whitley K, Zhao H, Hodinka RL. Epidemiology of human parvovirus B19 in children with sickle cell disease. Blood. 2004; 103(2):422-427.","DOI":"10.1182\/blood-2003-01-0069"},{"key":"72681","doi-asserted-by":"crossref","unstructured":"Majumdar S, Bean CJ, De Staercke C. Parvovirus B19 infection in sickle cell disease: an analysis from the Centers for Disease Control haemoglobinopathy blood surveillance project. Transfus Med. 2020; 30(3):226-230.","DOI":"10.1111\/tme.12671"},{"key":"72682","doi-asserted-by":"crossref","unstructured":"Owusu ED, Visser BJ, Nagel IM, Mens PF, Grobusch MP. The interaction between sickle cell disease and HIV infection: a systematic review. Clin Infect Dis. 2015; 60(4):612-626.","DOI":"10.1093\/cid\/ciu832"},{"key":"72683","unstructured":"World Health Organisation. Data on the size of the HIV epidemic. 2024. Publisher Full Text|"},{"key":"72684","doi-asserted-by":"crossref","unstructured":"Lori F, Kelly LM, Foli A, Lisziewicz J. Safety of hydroxyurea in the treatment of HIV infection. Expert Opin Drug Saf. 2004; 3(4):279-288.","DOI":"10.1517\/14740338.3.4.279"},{"key":"72685","doi-asserted-by":"crossref","unstructured":"Lowe SH, Prins JM, van der Lelie J, Lange JM. Does highly active antiretroviral therapy induce sickle cell crises?. Aids. 2002; 16(11):1572-1574.","DOI":"10.1097\/00002030-200207260-00024"},{"key":"72686","doi-asserted-by":"crossref","unstructured":"Bundy DG, Strouse JJ, Casella JF, Miller MR. Burden of influenza-related hospitalizations among children with sickle cell disease. Pediatrics. 2010; 125(2):234-243.","DOI":"10.1542\/peds.2009-1465"},{"key":"72687","doi-asserted-by":"crossref","unstructured":"Kao CM, Lai K, McAteer JM. Influenza vaccine effectiveness and disease burden in children and adolescents with sickle cell disease: 2012\u20102017. Pediatr Blood Cancer. 2020; 67(8):e28358.","DOI":"10.1002\/pbc.28358"},{"key":"72688","doi-asserted-by":"crossref","unstructured":"Michelon I, Vilbert M, Pinheiro IS. COVID-19 outcomes in patients with sickle cell disease and sickle cell trait compared with individuals without sickle cell disease or trait: a systematic review and meta-analysis. EClinicalMedicine. 2023; 66:102330.","DOI":"10.1016\/j.eclinm.2023.102330"},{"key":"72689","doi-asserted-by":"crossref","unstructured":"Minniti CP, Zaidi AU, Nouraie M. Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection. Blood Adv. 2021; 5(1):207-215.","DOI":"10.1182\/bloodadvances.2020003456"},{"key":"72690","doi-asserted-by":"crossref","unstructured":"Brousse V, Holvoet L, Pescarmona R. Low incidence of COVID-19 severe complications in a large cohort of children with sickle cell disease: a protective role for basal interferon-1 activation?. Haematologica. 2021; 106(10):2746-2748.","DOI":"10.3324\/haematol.2021.278573"},{"key":"72691","doi-asserted-by":"crossref","unstructured":"Xu S-W, Ilyas I, Weng J-P. Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol Sin. 2023; 44(4):695-709.","DOI":"10.1038\/s41401-022-00998-0"},{"key":"72692","doi-asserted-by":"crossref","unstructured":"Alkindi S, Elsadek RA, Al-Madhani A. Impact of COVID-19 on vasooclusive crisis in patients with sickle cell anaemia. Int J Infect Dis. 2021; 106:128-133.","DOI":"10.1016\/j.ijid.2021.03.044"},{"key":"72693","doi-asserted-by":"crossref","unstructured":"Dubois G, Virot E, Marie M, Poutrel S, Cannas G, Hot A. Impact of COVID\u201019 on incidence, clinical presentation, and prognosis of acute chest syndrome in patients with sickle cell disease. EJHaem. 2023; 4(4):970-976.","DOI":"10.1002\/jha2.768"},{"key":"72694","doi-asserted-by":"crossref","unstructured":"Walter O, Cougoul P, Maquet J. Risk of vaso-occlusive episode after exposure to corticosteroids in patients with sickle cell disease. Blood. 2022; 139(26):3771-3777.","DOI":"10.1182\/blood.2021014473"},{"key":"72695","doi-asserted-by":"crossref","unstructured":"Han J, Zhang X, Molokie RE. COVID-19 vaccination status and disease burden in patients with sickle cell disease. Br J Haematol. 2022; 199(4):e21-e24.","DOI":"10.1111\/bjh.18443"},{"key":"72696","doi-asserted-by":"crossref","unstructured":"Peng HK, Dombkowski KJ, Plegue MA. COVID-19 immunization coverage among people with sickle cell disease. JAMA Netw Open. 2024; 7(1):e2351618.","DOI":"10.1001\/jamanetworkopen.2023.51618"},{"key":"72697","doi-asserted-by":"crossref","unstructured":"Sahu T, Pande B, Verma HK. Infection and potential challenge of childhood mortality in sickle cell disease: a comprehensive review of the literature from a global perspective. Thalass Rep. 2023; 13(3):206-229.","DOI":"10.3390\/thalassrep13030019"},{"key":"72698","doi-asserted-by":"crossref","unstructured":"Rankine-Mullings A, Reid ME, Sang MM, Richards-Dawson M-A, Madden JMK. A retrospective analysis of the significance of haemoglobin SS and SC in disease outcome in patients with sickle cell disease and dengue fever. EBioMedicine. 2015; 2(8):937-941.","DOI":"10.1016\/j.ebiom.2015.07.002"},{"key":"72699","doi-asserted-by":"crossref","unstructured":"Elenga N, Nacher M, Trehan I. The Imperative of dengue vaccination for children with sickle cell disease. J Trop Pediatr. 2020; 66(3):245-247.","DOI":"10.1093\/tropej\/fmaa021"},{"key":"72700","doi-asserted-by":"crossref","unstructured":"Sonderup MW, Afihene M, Ally R. Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030. Lancet Gastroenterol Hepatol. 2017; 2(12):910-919.","DOI":"10.1016\/S2468-1253(17)30249-2"},{"key":"72701","doi-asserted-by":"crossref","unstructured":"Suddle AR. Management of liver complications in sickle cell disease. Hematology. 2019; 2019(1):345-350.","DOI":"10.1182\/hematology.2019000037"},{"key":"72702","doi-asserted-by":"crossref","unstructured":"Win N. Blood transfusion therapy for haemoglobinopathies.99-106.","DOI":"10.1002\/9780470988398.ch11"},{"key":"72703","doi-asserted-by":"crossref","unstructured":"Kwiatkowski DP. How malaria has affected the human genome and what human genetics can teach us about malaria. Am J Hum Genet. 2005; 77(2):171-192.","DOI":"10.1086\/432519"},{"key":"72704","doi-asserted-by":"crossref","unstructured":"Taylor SM, Parobek CM, Fairhurst RM. Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12(6):457-468.","DOI":"10.1016\/S1473-3099(12)70055-5"},{"key":"72705","doi-asserted-by":"crossref","unstructured":"Allison AC. Protection afforded by sickle-cell trait against subtertian malareal infection. Br Med J. 1954; 1(4857):290-294.","DOI":"10.1136\/bmj.1.4857.290"},{"key":"72706","doi-asserted-by":"crossref","unstructured":"Piel FB, Patil AP, Howes RE. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013; 381(9861):142-151.","DOI":"10.1016\/S0140-6736(12)61229-X"},{"key":"72707","doi-asserted-by":"crossref","unstructured":"Mkombachepa M, Khamis B, Rwegasira G, Urio F, Makani J, Luzzatto L. High incidence of malaria in patients with sickle cell disease. Am J Hematol. 2022; 97(10):E380-E381.","DOI":"10.1002\/ajh.26676"},{"key":"72708","doi-asserted-by":"crossref","unstructured":"Uyoga S, Olupot-Olupot P, Connon R. Sickle cell anaemia and severe Plasmodium falciparum malaria: a secondary analysis of the Transfusion and Treatment of African Children Trial (TRACT). Lancet Child Adolesc Health. 2022; 6(9):606-613.","DOI":"10.1016\/S2352-4642(22)00153-5"},{"key":"72709","doi-asserted-by":"crossref","unstructured":"Henrici RC, Sautter CL, Bond C. Decreased parasite burden and altered host response in children with sickle cell anemia and severe anemia with malaria. Blood Adv. 2021; 5(22):4710-4720.","DOI":"10.1182\/bloodadvances.2021004704"},{"key":"72710","doi-asserted-by":"crossref","unstructured":"Band G, Leffler EM, Jallow M. Malaria protection due to sickle haemoglobin depends on parasite genotype. Nature. 2022; 602(7895):106-111.","DOI":"10.1038\/s41586-021-04288-3"},{"key":"72711","doi-asserted-by":"crossref","unstructured":"Matuschewski K, Maier AG. Pas-de-deux: African Plasmodium falciparum adaptations to sickle hemoglobin. Trends Parasitol. 2022; 38(4):267-268.","DOI":"10.1016\/j.pt.2022.01.009"},{"key":"72712","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-D\u00edaz E, Ranford-Cartwright L. Evolutionary race: malaria evolves to evade sickle cell protection. Cell Host Microbe. 2022; 30(2):139-141.","DOI":"10.1016\/j.chom.2022.01.010"},{"key":"72713","doi-asserted-by":"crossref","unstructured":"Williams TN, Obaro SK. Sickle cell disease and malaria morbidity: a tale with two tails. Trends Parasitol. 2011; 27(7):315-320.","DOI":"10.1016\/j.pt.2011.02.004"},{"key":"72714","doi-asserted-by":"crossref","unstructured":"Duffy PE, Gorres JP, Healy SA, Fried M. Malaria vaccines: a new era of prevention and control. Nat Rev Microbiol. 2024; 22(12):756-772.","DOI":"10.1038\/s41579-024-01065-7"},{"key":"72715","doi-asserted-by":"crossref","unstructured":"Farid Z, Patwardhan VN, Darby WJ. Parasitism and anemia. Am J Clin Nutr. 1969; 22(4):498-503.","DOI":"10.1093\/ajcn\/22.4.498"},{"key":"72716","doi-asserted-by":"crossref","unstructured":"Ahmed SG, Uraka J. Impact of intestinal parasites on haematological parameters of sickle-cell anaemia patients in Nigeria. East Mediterr Health J. 2011; 17(9):710-713.","DOI":"10.26719\/2011.17.9.710"},{"key":"72717","doi-asserted-by":"crossref","unstructured":"Onoh EA, Muoneke UV, Young EE, Nwatu BC. Effect of intestinal helminth infection on haemoglobin levels and frequency of vaso-occlusive crises in children with sickle cell anaemia (SCA) attending Federal Teaching Hospital, Abakaliki, Nigeria. PAMJ-CM. 2020; 3(190):23506.","DOI":"10.11604\/pamj-cm.2020.3.190.23506"},{"key":"72718","doi-asserted-by":"crossref","unstructured":"Navalkele P, \u00d6zg\u00f6nenel B, McGrath E, Lephart P, Sarnaik S. Invasive pneumococcal disease in patients with sickle cell disease. J Pediatr Hematol Oncol. 2017; 39(5):341-344.","DOI":"10.1097\/MPH.0000000000000858"},{"key":"72719","unstructured":"Sickle Cell Society. Sickle cell disease in childhood: standards and recommendations for clinical care. 2019."},{"key":"72720","doi-asserted-by":"crossref","unstructured":"Anderson EC, Begg NT, Crawshaw SC, Hargreaves RM, Howard AJ, Slack MPE. Epidemiology of invasive Haemophilus influenzae infections in England and Wales in the pre-vaccination era (1990-2). Epidemiol Infect. 1995; 115(1):89-100.","DOI":"10.1017\/S0950268800058155"},{"key":"72721","unstructured":"Khattak ZE, Anjum F. Haemophilus influenzae Infection. 2024. Publisher Full Text|"},{"key":"72722","unstructured":"Cohn AC, MacNeil JR, Clark TA. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013; 62(RR-2):1-28."},{"key":"72723","doi-asserted-by":"crossref","unstructured":"Masters EA, Ricciardi BF, de Mesy Bentley KL, Moriarty TF, Schwarz EM, Muthukrishnan G. Skeletal infections: microbial pathogenesis, immunity and clinical management. Nat Rev Microbiol. 2022; 20(7):385-400.","DOI":"10.1038\/s41579-022-00686-0"},{"key":"72724","doi-asserted-by":"crossref","unstructured":"Anand AJ, Glatt AE. Salmonella osteomyelitis and arthritis in sickle cell disease. Semin Arthritis Rheum. 1994; 24(3):211-221.","DOI":"10.1016\/0049-0172(94)90076-0"},{"key":"72725","doi-asserted-by":"crossref","unstructured":"Belis\u00e1rio AR, Blatyta PF, Vivanco D. Association of HIV infection with clinical and laboratory characteristics of sickle cell disease. BMC Infect Dis. 2020; 20(1):638.","DOI":"10.1016\/j.htct.2020.10.059"},{"key":"72726","doi-asserted-by":"crossref","unstructured":"Lennon P, Crotty M, Fenton JE. Infectious mononucleosis. BMJ. 2015; 350:h1825.","DOI":"10.1136\/bmj.h1825"},{"key":"72727","doi-asserted-by":"crossref","unstructured":"van den Enden E. Pharmacotherapy of helminth infection. Expert Opin Pharmacother. 2009; 10(3):435-451.","DOI":"10.1517\/14656560902722463"},{"key":"72728","doi-asserted-by":"crossref","unstructured":"Escobedo AA, Almirall P, Alfonso M, Cimerman S, Rey S, Terry SL. Treatment of intestinal protozoan infections in children. Arch Dis Child. 2009; 94(6):478-482.","DOI":"10.1136\/adc.2008.151852"},{"key":"72729","doi-asserted-by":"crossref","unstructured":"Rees DC, Brousse VAM, Brewin JN. Determinants of severity in sickle cell disease. Blood Rev. 2022; 56:100983.","DOI":"10.1016\/j.blre.2022.100983"},{"key":"72730","doi-asserted-by":"crossref","unstructured":"Piel FB, Rees DC, DeBaun MR. Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. Lancet Haematol. 2023; 10(8):e633-e686.","DOI":"10.1016\/S2352-3026(23)00096-0"},{"key":"72731","doi-asserted-by":"crossref","unstructured":"Pourdieu C, El Hoss S, Le Roux E. Relevance of Howell-Jolly body counts for measuring spleen function in sickle cell disease. Am J Hematol. 2023; 98(5):E110-E112.","DOI":"10.1002\/ajh.26879"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11832\/77792","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11832\/78090","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11832\/77792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:40Z","timestamp":1794046060000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":138,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285066","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}